EZH2 and diffuse large B-cell lymphoma: The main gain-of-function mutation identified in DLBCL and FL patients includes a tyrosine deletion (Y641) at the EZH2 SET domain that increases the levels of H3K27me3, promoting a repressed state of cell differentiation and the repression of tumor suppressor genes (Morin et al., 2010; McCabe et al., 2012a).